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Abstract
Background/Objective: Ivermectin has been the keystone of onchocerciasis control for the last 25 years. Sub-optimal
responses to the drug have been reported in Ghanaian communities under long-term treatment. We assessed, in two
Cameroonian foci, whether the microfilaricidal and/or embryostatic effects of ivermectin on Onchocerca volvulus have been
altered after several years of drug pressure.
Methods: We compared the dynamics of O. volvulus skin microfilarial densities after ivermectin treatment in two cohorts
with contrasting exposure to this drug: one received repeated treatment for 13 years whereas the other had no history of
large-scale treatments (referred to as controls). Microfilarial densities were assessed 15, 80 and 180 days after ivermectin in
122 multiply treated and 127 ivermectin-naı̈ve individuals. Comparisons were adjusted for individual factors related to
microfilarial density: age and number of nodules.
Findings: Two weeks post ivermectin, microfilarial density dropped equally (98% reduction) in the ivermectin-naı̈ve and
multiply treated groups. Between 15 and 180 days post ivermectin, the proportion of individuals with skin microfilariae
doubled (from 30.8% to 67.8%) in controls and quadrupled (from 19.8% to 76.9%) in multiply treated individuals but the
mean densities remained low in both sites. In fact, between 15 and 80 days, the repopulation rate was significantly higher in
the multiply treated individuals than in the controls but no such difference was demonstrated when extending the follow-
up to 180 days. The repopulation rate by microfilariae was associated with host factors: negatively with age and positively
with the number of nodules.
Conclusion: These observations may indicate that the worms from the multi-treated area recover mf productivity earlier but
would be less productive than the worms from the ivermectin-naı̈ve area between 80 and 180 days after ivermectin.
Moreover, they do not support the operation of a strong cumulative effect of repeated treatments on the fecundity of
female worms as previously described.
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Introduction
In the year 2012, onchocerciasis – or river blindness – is on the
verge of being eliminated from some foci in Latin America [1]
and, in Africa, evidence of the feasibility of its elimination is
emerging [2,3]. Since the mid-nineties, onchocerciasis control
programs have mainly relied on the anthelmintic properties of a
single drug, ivermectin. This drug has two main effects on
Onchocerca volvulus, the parasite responsible for onchocerciasis. The
first effect is a killing of the embryonic stage of the parasite, the
microfilariae (mf). This so called microfilaricidal effect results in a
dramatic decrease of microfilarial density in the skin, starting a few
hours following ivermectin intake and reaching its nadir about 1-2
months later [4]. The host immune response is thought to
contribute to drug induced microfilarial destruction [5].
The second effect of ivermectin on O. volvulus prevents the
release of mf from the female worms’ uteri and is called the
embryostatic effect. The newly produced mf are blocked inside the
uteri where they die and degenerate within four weeks post-
ivermectin [6]. This effect is temporary and mf start progressively
repopulating the skin and other tissues about three months after
treatment [4].
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Since the embryostatic effect of ivermectin is temporary,
treatment has to be repeated to maintain the microfilarial densities
as low as possible. By reducing the microfilarial reservoir,
ivermectin treatments provide a double benefit: at individual
level, they prevent or limit the development of clinical signs
associated with onchocerciasis, while at the community level, they
reduce the intensity of transmission, and consequently the
incidence of infection.
In areas covered by the African Programme for Onchocerciasis
Control (APOC), populations receive ivermectin once a year
through the community-directed treatment with ivermectin
(CDTI) strategy. In 2010, after 15 years of activity, APOC and
Non-Governmental Development Organizations have helped the
endemic countries to successfully extend ivermectin coverage to a
total population of approximately 75.8 million people in 16
countries across sub-Saharan Africa [7]. In most CDTI projects,
the therapeutic coverage now exceeds the targeted threshold of
65% of the total population. High coverage ensures significant
epidemiological impact of CDTIs and the World Health
Organization (WHO) estimates that the loss of nearly one million
disability-adjusted life years (DALYs) has already been averted and
that the prevalence of infection has decreased by about 73%
compared with pre-APOC levels [8].
Shift from control to elimination is now on top of the agenda of
APOC management and stakeholders. However, on the fringe of
this promising picture, there have been reports of drug under-
achievement in some communities from Ghana under long-term
treatment with ivermectin [9–12]. In these communities, a
number of individuals, qualified as sub-optimal responders,
showed a faster than expected repopulation of the skin by mf.
Embryograms of adult female worms [13] performed 90 days after
ivermectin treatment revealed a high proportion of worms
exhibiting reproductive activity (defined by the presence of
developmental stages, i.e. morula, coiled mf or stretched mf, in
the uteri). These observations raise the possibility that ivermectin
resistance may be emerging, which would manifest itself as a rapid
resumption of mf release by the adult female worms, resulting in
repopulation of the skin with mf earlier than previously reported
[6]. In addition to phenotypic expression of sub-optimal response,
a number of studies have shown genetic changes in O. volvulus
populations subjected to several years of ivermectin treatment [14–
21]. Among those genes under ivermectin-driven selection, P-
glycoprotein (PGP)and beta-tubulin have been shown to be
associated with ivermectin resistance in helminth infection of
livestock [22,23].
To date, a direct association between phenotypic resistance and
ivermectin-driven genetic selection has yet to be proven but
observations made so far, underscored by the massive drug
pressure exerted on O. volvulus, warrant active parasitological
monitoring of ivermectin efficacy. In the present study, we
compared the response profiles of O. volvulus to ivermectin between




The objective of this study, conducted in 2007–2008, was to
assess whether the microfilaricidal and/or embryostatic effects of
ivermectin on O. volvulus have been altered after several years of
drug pressure. To this end, we have compared the dynamics of O.
volvulus skin microfilarial densities after ivermectin treatment in
two Cameroonian populations with different histories of exposure
to the drug: one has benefitted from repeated treatments for 13
years whereas the other originated from an onchocerciasis
endemic area where no large-scale treatment has ever been
organized.
Study areas and selection of participants
A group of ivermectin-naı̈ve patients was recruited from 10
neighbouring communities of the Nkam valley (Bayon, Ekom-
Nkam, Mboue, Mpaka, Mbarembeng, Bakem 1, Bakem 2, Lonze,
Manjibo and Mounko), a forested area located in the Littoral
Region which had neither benefitted from any mass ivermectin
treatment at the outset of the study nor vector control. As loiasis
was known to be present in this area, Loa loa microfilaremia was
also assessed for each subject. Participants with more than
30,000 mf/ml of blood, and who were consequently at risk of
developing severe adverse reaction to ivermectin, were excluded
from the study. Throughout the text, we will refer to this
ivermectin-naı̈ve area as the control area.
The group of patients subjected to multiple ivermectin
treatments was recruited from 22 communities of the Mbam
valley (Babetta, Balamba 1, Balamba 2, Bayomen, Bialanguena,
Biamo, Biatsotta, Boalondo, Bombatto, Botatango, Boura 1,
Diodaré, Gah-Bapé, Kalong, Kon, Lablé, Lakpang, Ngomo,
Ngongol, Nyamanga, Nyamsong and Yébékolo). In these com-
munities, annual large-scale treatments with ivermectin have been
conducted since 1994. In addition, these patients had taken part in
a clinical trial conducted between 1994 and 1997 aimed at
evaluating the macrofilaricidal potential of ivermectin [24].
Depending on their treatment group during the trial, they
received 4 to 13 doses of ivermectin over this 4-year period. To
date, no vector control has ever been implemented in this area.
The patients eligible for the present study were males aged 25
years and over, presenting with at least two palpable onchocercal
nodules, but otherwise in good state of health. As ivermectin had
been distributed, for over 10 years, in areas not very far from the
Nkam valley, eligible subjects of the control population were asked
whether they had been previously treated with ivermectin and
Author Summary
Millions of Africans and thousands of Latin Americans are
infected with Onchocerca volvulus, the filarial worm
responsible for onchocerciasis. Since the mid-1990s,
control programs rely on annual or six-monthly commu-
nity treatments with the only safe drug available,
ivermectin. If sustained for another 10–15 years, this
strategy could lead to elimination of onchocerciasis.
Unfortunately, there have been reports of low response
to the drug in Ghanaian communities under long-term
treatment. Here, we compared the response of O. volvulus
to ivermectin between a Cameroonian population repeat-
edly treated and an ivermectin-naı̈ve population. Skin
parasite density was assessed before and 15, 80 and 180
days after treatment. Parasite density dropped equally in
the two groups (,98% reduction) by 15 days, in
accordance with the expected effect of ivermectin at this
time point. In the multi-treated subjects, the repopulation
rate of the skin by microfilariae was higher than in the
controls from 15 to 80 days after treatment but the
microfilarial levels reached similar levels six months after
treatment in the two groups. Thirteen years of large-scale
treatments may have selected worms less sensitive to the
drug. In addition, those treatments had little if any
cumulative effect on skin parasite repopulation after an
additional treatment.
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those individuals who had either received the drug during the
previous five years (2003–2007) or on three or more occasions
whatever the dates were excluded from the analyses.
Sample collection and processing
In both sites, individual skin microfilarial density was assessed
before the treatment with ivermectin (D0). Treatment was given
under direct observation of investigators. We made the assumption
that individuals presenting with no or only one single mf in their
skin snips at D0, i.e. at least one year after a previous ivermectin
treatment (or at their parasitic equilibrium for untreated subjects),
would not exhibit skin mf during the six months following
ivermectin treatment and thus decided that only those individuals
who had at least two mf in the total of their two skin biopsies on
D0 would be re-sampled on D15, D80 and D180. Indeed, it would
not have been ethically acceptable to perform additional invasive
and painful examinations on individuals with no or only one mf to
observe a predictable output. The veracity of this assumption was
assessed by examining the response profile of the 10% of the less
densely infected subjects of each group.
Skin microfilarial densities were assessed using a slightly
modified version of the protocol recommended by the Onchocer-
ciasis Control Programme in West Africa (OCP) [25]. Two skin
biopsies (one from each posterior iliac crest) were taken using a
2 mm Holth-type punch and, after 24 hours incubation in saline,
all emerged mf were counted under a microscope. Since not all mf
present in a skin snip have emerged at 30 minutes, we chose to
examine all the skin biopsies at 24 h (rather than at 30 minutes or
at 24 h for those negative at 30 minutes as recommended by the
OCP) to have a more accurate assessment of microfilarial density.
In addition, all skin snips were weighed with 0.1 mg precision,
allowing a more accurate assessment of the intensity of infection
[26]. Throughout the analysis, the microfilarial densities were
expressed in mf per milligram of skin (mf/mg).
All patients also underwent a detailed clinical examination
before receiving treatment and the location of all palpable
onchocercal nodules was recorded on a standard body chart.
Ethical clearance and agreement
The study received ethical clearance from the National Ethics
Committee of Cameroon and was approved by the Cameroonian
Ministry of Public Health. All the participants signed an informed
consent form before undergoing the first examination.
Statistical analyses
The main objective of the analysis was to compare the dynamics
of microfilarial densities between two groups: a group of subjects
who had been exposed to multiple ivermectin treatments and a
control group, composed with individuals living in an ivermectin-
naı̈ve area.
In the first instance, we compared, between the two groups, (a)
the distribution of microfilarial density for each time of observa-
tion, and (b) the distribution of individual variation in microfilarial
density from D15 to D80 and from D80 to D180. Those
comparisons were performed using the nonparametric Kolmo-
gorov-Smirnov test.
Then, since we previously showed that individual factors such as
age and number of palpable nodules could influence the temporal
dynamics of skin microfilarial densities after a first dose of
ivermectin [27], the comparisons were performed using a
multivariate regression model, which allows testing the group-
effect while adjusting on individual factors. We tested several
models that seemed suitable to handle overdispersed data [28]
while accounting for the clustered structure of the dataset (with
repeated measures per individual). The dynamics of the
microfilarial densities during the D0-D180 period was best
described using a zero-inflated negative binomial model with
robust variance estimates for each parameter [29]. This model
was computed using the zinb procedure with the cluster-
correlated robust variance estimates available in the Stata
software [30,31]. In this model, the variable of interest was the
post-treatment microfilarial density and the regressors comprised
host age, the number of palpable onchocercal nodules, the study
group (ivermectin-naı̈ve or multiply treated), and two interaction
terms: one between the study group and the number of days after
ivermectin treatment (0 (i.e. prior to treatment), 15, 80 and 180)
and one between the study group and the number of nodules.
Inclusion of the former interaction term allowed microfilarial
repopulation to vary with time post treatment in a different
manner for each population. Inclusion of the latter allowed the
effect of number of nodules to vary between the groups, i.e. to
test whether the contribution of adult worms to microfilarial
density, for a given number of nodules, was different between the
groups.
In this model, we chose to set up D15, rather than D0, as the
baseline time point, so that the model can conveniently assess the
change in microfilarial density due to the microfilaricidal effect of
ivermectin (between D0 and D15), and then to its embryostatic
effect (from D15 to D80 and from D15 to 180). It is true that
repopulation of the skin by mf normally starts to occur
progressively by 3 months [4]. However, we hypothesized that
sub-optimally responding worms potentially present in the multi-
treated group could resume their mf production before 3 months,
and that could be indicated by a different dynamics of microfilarial
density between D15 and D80.
Results
Population description at the outset of the study
In the control area, skin snips and calibrated blood smears were
obtained from 194 individuals. Among the 30 subjects who
harboured L. loa microfilaraemia, three presented with more than
30,000 mf/ml and could not be safely given ivermectin.
Of the 191 subjects eligible for ivermectin treatment in this
area, 167 (87.4%) had at least one positive skin snip and 159
(83.2%) of them presented with at least two mf in their two skin
snips. Among those 159 individuals, 30 declared having taken
ivermectin during the previous five years and another
individual declared having taken the drug five times before
2003. These 31 individuals were excluded from subsequent
analyses. In addition, one individual showed suspicious post-
treatment microfilarial densities which suggested that he had
probably not swallowed the ivermectin tablets: 34.1 mf/mg on
D0, absent on D15, 69.8 mf/mg on D80 and 30.2 mf/mg on
D180. This individual was also excluded from statistical
analyses, leading to a total of 127 available subjects for the
subsequent analyses in the Nkam valley. The median age and
mean number of onchocercal nodules in these 127 subjects
were respectively 44 years and 3.4 nodules/person (standard
deviation (s.d.) 1.5).
In the Mbam valley (repeatedly treated area), 205 subjects
provided skin snips at D0, from whom 138 (67.3%) had at least
one positive skin-snip but only 122 (59.5%) presented with a total
of at least two mf in the two skin snips. All these 122 individuals
received ivermectin and were included in subsequent analyses.
The median age and mean number of onchocercal nodules in
these 122 subjects were respectively 45 years and 4.5 nodules/
person (s.d. 2.4).
Monitoring Ivermectin Efficacy in Onchocerciasis
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Response profiles to ivermectin treatment
Microfilarial densities at the different time points of follow-up
are shown in Figure 1 and their respective arithmetic means
(calculated including zeros) are given in Table 1. As it could be
expected, the microfilarial densities recorded just before the 2007
treatment were significantly higher in individuals from the
ivermectin naı̈ve area than in those from the multiply treated
one (Figure 1, Table 1).
Two weeks after ivermectin (D15), the proportions of subjects
with skin mf dropped to 30.8% and 19.8% in the control and
multiply treated groups, respectively, a percent reduction equiv-
alent to ,70% and 80%. At this time point, the microfilarial
densities had dropped in both groups in equal proportions,
equivalent to a ,98% reduction rate of the pre-treatment value
(Table 1).
Between 15 and 80 days after ivermectin, the proportions of
subjects with mf increased by a third to 40.2%, and doubled to
41.1% in the control and multiply treated group, respectively. The
mean microfilarial density continued to decrease in the control
group but showed an increase in the multiply treated group.
However, due to the high variability in microfilarial density, mean
values are poorly representative of the panel of actual individual
responses and, as shown in Figure 2, from D15 to D80, the
subjects showed different profiles of evolution of their microfilarial
Figure 1. Ivermectin efficacy against Onchocerca volvulus in ivermectin-naı̈ve (#) and multiply treated subjects (D). Microfilarial density
was assessed before and 15, 80 and 180 days after ivermectin in two groups of subjects with different exposure to ivermectin. Bars indicate the
median and inter-quartile range of microfilarial density, including zeros.
doi:10.1371/journal.pntd.0002084.g001
Table 1. Onchocerca volvulus microfilarial densities (mf/mg) in ivermectin-naı̈ve and multiply treated subjects before and after
ivermectin.









Day 0 127/127 (100) 21.8 (24.5) 27.5 122/122 (100) 11.8 (23.9) 48.4 0.001
Day 15 36/117 (30.8) 0.4 (1.5) 5.6 23/116 (19.8) 0.2 (0.7) 2.5 0.429
Day 80 47/117 (40.2) 0.3 (0.7) 1.6 46/112 (41.1) 0.6 (3.2) 17.1 0.999
Day 180 82/121 (67.8) 2.2 (4.6) 9.6 93/121 (76.9) 2.5 (6.1) 14.9 0.366
*arithmetic mean of microfilarial densities (mf/mg), including zero counts.
{standard deviation.
1VMR = variance to mean ratio.
#distributions of microfilarial densities were compared between the two groups using Kolmogorov-Smirnov test.
doi:10.1371/journal.pntd.0002084.t001
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density. In the multiply treated group, a higher proportion of
participants showed an increase in microfilarial density than in the
control group (38.7% vs 26.7%) (Table 2). At the same time, a
higher proportion of subjects showed a decrease in the control
group than in the multiply treated group (22.1% vs 11.3%)
(Table 2). However, comparison of distribution of individual
variations from 15 to 80 days post treatment between the two
groups did not yield a significant difference (Kolmogorov-Smirnov
test, p = 0.171).
From 80 days after ivermectin onwards, reappearance of mf in
the skin continued to occur (Table 2, Figure 3). At 180 days post
ivermectin, the proportion of subjects with skin mf doubled
(increased to 67.8%) in the control group and quadrupled
(increased to 76.9%) in the multiply treated one in relation to
Figure 2. Evolution of Onchocerca volvulus microfilarial density (mf/mg) between 15 and 80 days after ivermectin treatment.
Microfilarial density at D80 is plotted against density at D15 (scatterplots), for each individual, in ivermectin-naı̈ve and multiply treated subjects.
Distribution of individual variation between 15 and 80 days post-treatment is also given (histograms) for the ivermectin-naı̈ve and multiply treated
subjects (positive difference means an increase between D15 and D80). Lines in scatterplots represent slope = 1, i.e no change in microfilarial density.
X-axis below histograms indicates central values of 2 mf/mg width bins (e.g. 0 indicates microfilarial density between 21 and 1).
doi:10.1371/journal.pntd.0002084.g002
Table 2. Evolution of Onchocerca volvulus microfilarial density after ivermectin treatment in ivermectin-naı̈ve and multiply treated
subjects.










- increased 0 0 26.7 38.7 66.9 74.8
- decreased 100 100 22.1 11.3 0.9 2.1
- levelled off* - - 51.2 50.0 32.2 23.1
*all individuals in this category presented with no detectable skin microfilariae.
doi:10.1371/journal.pntd.0002084.t002
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the values at D15. The mean microfilarial densities remained low
in both groups during this time period and reached similar mean
values at D180 (2.2 mf/mg in the ivermectin-naı̈ve group vs
2.5 mf/mg in the multiply treated group) (Table 1). At D180, only
six (5.0%) and seven (5.8%) individuals had microfilarial densities
above 10 mf/mg in the control and multiply treated groups,
respectively. The distributions of individual variations from 80 to
180 days post-treatment were similar in the two groups
(Kolmogorov-Smirnov test, p = 0.345).
In Table 3, we focussed on the microfilarial densities of the 10%
less densely infected subjects from each group to assess our
assumption that subjects with a very low microfilarial density
before treatment would remain mf negative during the six-month
follow-up. The tenth percentile of microfilarial density at D0 for
the control and multiply treated groups were 1.3 mf/mg and
0.7 mf/mg, respectively. Up to D80, the proportion of subjects
showing mf remained low in both sub-groups and those few
individuals with a positive skin snip had very low densities.
Figure 3. Evolution of Onchocerca volvulus microfilarial density (mf/mg) between 80 and 180 days after ivermectin treatment.
Microfilarial density at D180 is plotted against density at D80 (scatterplots), for each individual, in ivermectin-naı̈ve and multiply treated subjects.
Distribution of individual variation between 80 and 180 days post-treatment is also given (histograms) for the ivermectin-naı̈ve and multiply treated
subjects (positive difference means an increase between D80 and D180). Lines in scatterplots represent slope = 1, i.e no change in microfilarial
density. X-axis below histograms indicates central values of 2 mf/mg width bins (e.g. 0 indicates microfilarial density between 21 and 1).
doi:10.1371/journal.pntd.0002084.g003
Table 3. Post-ivermectin microfilarial densities of the 10% less densely infected subjects before treatment.
D15 D80 D180
Group Multiply treated Ivermectin-naı̈ve Multiply treated Ivermectin-naı̈ve Multiply treated Ivermectin-naı̈ve
No Examined 13 15 12 15 13 14
No Positives 1 2 2 3 9 8
Mean mf density of
positives (mf/mg)
0.2 0.3 0.5 0.3 1.2 1.1
doi:10.1371/journal.pntd.0002084.t003
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However, at D180, most subjects presented with mf, though still
exhibiting moderate microfilarial densities.
Results of the regression model estimated concurrently on the 4
time points (D0, D15, D80 and D180) are presented in Table 4.
They indicate that the decrease in microfilarial density two weeks
after ivermectin was similar in the two groups (p = 0.807).
Regarding the subsequent period (from D15 to D80), the model
indicates a higher increase in microfilarial density in the multiply
treated individuals than in the controls (Incidence Rate Ratio
(IRR) = 4.045, 95% CI (2.168–7.547), p = 0.001). When consid-
ering the longer period D15 to D180, the difference in the increase
rate between the two groups was attenuated. The rate tended to be
higher in the multiply treated individuals but the difference failed
to reach statistical significance (IRR = 2.214, 95% CI (0.835–
5.875), p = 0.11). At D180, the distribution of microfilarial
densities was similar in the two groups (Kolmogorov-Smirnov
test, p = 0.366).
Beside this, the model shows that age was negatively associated
with post-treatment microfilarial densities (p = 0.009), with youn-
ger individuals more likely to have higher densities than their older
counterparts, and that the number of nodules was positively
associated with the post-treatment microfilarial densities
(p = 0.002) (Table 4). However, the influence of the number of
nodules on microfilarial density was not different between the two
study groups (p = 0.689). The mean microfilarial density (and its
95% CI), as predicted by the model for the different times of
follow-up, is presented for each of the two study groups in Figure 4.
In addition, the frequency distributions of observed and predicted
values at the different time points are shown in Figures 5 and 6 for
the control group and the multiply treated group, respectively.
Discussion
To assess whether the effects of ivermectin on O. volvulus had
been altered after repeated treatments, we aimed at comparing the
dynamics of microfilarial densities from 0 to 180 days post-
ivermectin between two populations with contrasting histories of
treatment (an ivermectin-naı̈ve population and a population
exposed to 13 years of treatments) but otherwise similar. Despite
our efforts to compose two strictly matched groups (on age, sex
and level of infection), the level of infection at day 0 was not even
in the two groups, with higher number of nodules and lower mf
density in the multiply-treated group than in the control one. The
difference in microfilarial density between the two groups at day 0
was expected as a result of previous ivermectin treatments in the
Mbam valley. However, the higher number of nodules in the
multi-treated participants can result from (a) the fact that the initial
level of endemicity of onchocerciasis in the Mbam valley was
higher than that in the Nkam valley but also from (b) a possible
bias in the inclusion process. Regarding (a), the higher level of
endemicity of onchocerciasis in the Mbam valley compared to that
in the Nkam valley raises the concern that the worm populations,
in particular the age and fecundity of female worms, may differ as
a consequence of dissimilar transmission dynamics in the two sites.
Table 4. Zero-inflated negative binomial regression of post ivermectin microfilarial density in ivermectin-naı̈ve and multiply
treated subjects.
Incidence rate-ratio* [95% Confidence Interval] P.z
Date of follow-up"
Day 0 63.174 31.243 – 127.540 0.001
Day 15 1
Day 80 0.796 0.479 – 1.322 0.379
Day 180 6.007 2.744 – 13.148 0.001
Study group"
Ivermectin-naı̈ve 1
Multiply treated 0.310 0.111 – 0.860 0.024
Age 0.981 0.967 – 0.995 0.009
Number of palpable nodules 1.186 1.064 – 1.320 0.002
Number of palpable nodules x Study group 1.047 0.835 – 1.312 0.689
Date x Study group
Day 0 x Multiply treated 1.114 0.467 – 2.656 0.807
Day 15 x Ivermectin-naı̈ve 1
Day 80 x Multiply treated 4.045 2.168 – 7.547 0.001
Day 180 x Multiply treated 2.214 0.835 – 5.875 0.110
Constant 0.469 0.150 – 1.147 0.194
Zero inflation part
Number of palpable nodules 20.415 20.558 – 20.273 0.001
Constant 1.701 1.336 – 2.167
Dispersion parameter (k) 0.618 0.478 – 0.799
*Results are presented as incidence rate ratios (IRR) for the negative binomial model. For quantitative variables (e.g. age), IRR is the ratio of mean O. volvulus microfilarial
density when explanatory factor is [x+1] to mean microfilarial density when explanatory factor is [x] (holding all other variables constant). For qualitative variables (e.g.
study group) the IRR is the ratio of mean microfilarial density for that category compared to the baseline category.
"Baselines for categorical variables are Date of follow-up = D15 and Study group = ivermectin-naı̈ve.
doi:10.1371/journal.pntd.0002084.t004
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Indeed, in Liberia, it has been observed that the proportions of old
and dead female worms were generally higher in hypo-endemic
villages (28% and 18%, respectively) than in hyper-endemic ones
(7% and 12%) [32]. We analyzed the population of adult worms
collected in the Mbam valley at the outset of the 1994–1998
clinical trial [33]. In this study, the mean number of fecund female
worms per nodule was similar in the four groups of villages defined
by endemicity level (0.99, 0.90, 0.97 and 0.99 female/nodule in
the respective community microfilarial load classes 10–40, 41–60,
61–70 and .70 mf/skin snip). In addition, embryograms of adult
worms collected as part of the present study have been analyzed.
Preliminary results indicate that, on day 0 (before ivermectin
treatment was given in 2007), the female worms’ fecundity was
similar in the two sites [34]. Further analysis of the worm
populations from the two sites would be needed to assess precisely
whether they differ significantly or not but the observations made
so far suggest that they are not dissimilar. Regarding (b), to be
included in the follow-up, participants had to present with, in
addition to at least two palpable nodules, at least two mf in their
skin snips before ivermectin was given. Amongst the respectively
191 and 205 subjects presenting with at least two palpable nodules
in the control and multiply treated group, a significantly higher
proportion of participants were excluded from the multiply treated
population (40.5%) than from the ivermectin-naı̈ve population
(16.8%). This may have resulted in the selection of the most
heavily infected subjects (in terms of adult worm load) in the multi-
treated area where the participants have had their microfilarial
density decreased by previous ivermectin treatments. The
rationale for not including individuals with less than two mf in
the total of their two skin snips at D0 in the follow-up was to avoid
less informative invasive examinations, based on the hypothesis
that most subjects, if not all, with a very low microfilarial density
before treatment (i.e. at least one year after a previous ivermectin
treatment or at their parasitic equilibrium for untreated subjects)
would remain mf negative during the six-month follow-up. The
response profiles of the less densely infected subjects (the closest
similar subjects to those who have not been included) show that
this assumption may be acceptable up to D80. However, at D180,
significant proportions of subjects had positive skin-snips. If a
similar trend occurs in individuals with less than 2 mf/2ss before
ivermectin treatment, it may be of relevance to re-examine them
at six months or subsequent dates after treatment. To test further
whether the exclusion of the subjects had an impact on the
comparison between the groups, we also assessed the zero-inflated
model on the full sample of subjects examined at D0 (i.e. including
the excluded subjects), generating unobserved post-treatment data
under two extreme scenarios. Under the first one, we assumed that
the microfilarial density of all excluded subjects dropped to zero at
D15 and remained at zero at the subsequent time points. Under
the second one, we assumed that the microfilarial density of all
excluded subjects dropped to zero at D15 and remained at zero at
D80 but reached its pre-treatment level at D180. In both cases, the
results were very similar to those obtained when the subjects with
less than 2 mf/2ss before ivermectin treatment were not included
(results not shown), suggesting that their exclusion did not bias the
results, in particular the difference of repopulation rate observed
between the two groups between D15 and D80.
Nevertheless, to account for this difference in number of
nodules, we have assessed the possible effect of exposure to
ivermectin (ivermectin-naı̈ve vs multiply treated) while adjusting
on the number of nodules (as a covariate in the multivariate
model). Since the distributions of number of nodules in the two
groups of subjects still largely overlap, we think that our study
provides robust and reliable results. This being said, were another
similar study to be conducted in the future, we would suggest
performing a strict matching of individuals on the number of
palpable nodules.
Fifteen days after ivermectin treatment, microfilarial densities
were expected to be very low [4]. Our observations confirmed that
they were indeed very low in both study groups. Despite a higher
decrease in the proportion of subjects with mf in the multiply
treated group from day 0 to day 15, the longitudinal model
Figure 4. Observed and predicted mean microfilarial density in ivermectin naı̈ve (diamonds) and multiply treated (squares) groups.
Filled symbols represent observed means and open symbols represent zero-inflated negative binomial predictions of the mean. Bars indicate 95%
confidence intervals for both observations and predictions.
doi:10.1371/journal.pntd.0002084.g004
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indicated that the decrease in microfilarial density was similar in
the two groups. As a first observation of this study, the very low
levels of skin mf 15 days post-treatment in the multiply treated
group do not indicate any alteration in the microfilaricidal effect of
ivermectin after 13 years of large-scale use in the area. These
results confirm those observed in Ghana [11], and that the percent
reductions in microfilarial load are also similar to those expected in
a normally responding parasite population [4].
Between two weeks and 80 days post-ivermectin treatment,
most subjects of both groups did not show detectable skin mf, with
even proportions in the control and multi-treated groups (51.1%
and 50%, respectively), yet microfilarial repopulation of the skin
occurred in a minority of subjects (26.7% and 38.7% in the control
and multi-treated groups, respectively). Results of multivariate
analysis conducted on this time period (D15–D80) indicate that,
on average, the rate of skin repopulation was higher in the multi-
treated group than in the control group (IRR ,4). This trend is, in
part, due to the higher proportion of subjects whose microfilarial
load increased between D15 and D80 in the multi-treated group.
This may indicate that the embryostatic effect of ivermectin has
been relaxed more rapidly and/or in a greater number of worms
in subjects from the multi-treated areas than in those from the
ivermectin-naı̈ve zone.
When extending the follow-up from 15 days to six months after
ivermectin, the difference between the groups was attenuated and
did not reach statistical significance (IRR ,2, p = 0.11). At six
months post-treatment, the distribution of microfilarial density was
similar in the two groups. This may indicate that, after ivermectin,
the worms from the multiply treated group may recover mf
productivity earlier (more worms resume mf productivity between
D15 and D80 in the multiply treated group) than the worms from
the naı̈ve one but, from D80 to D180, the former worms would be
less productive than the latter. This picture is in accordance with
previous findings, in which repeated ivermectin treatments have
been found to cause a genetic selection of O. volvulus associated
with a lower reproductive rate in female worms [18]. It would
therefore be of utmost interest to perform genetic analysis of the
worms collected as part of the present study to assess whether this
difference is genetically driven.
The patients included in the multi-treated group were given
annual or 3-monthly ivermectin treatments (thus 4 or 13 doses)
between 1994 and 1997 as part of a carefully monitored clinical
trial. Subsequently, during 9 years, they were offered ivermectin
once a year as part of CDTI campaigns. Thus, before the
treatment given as part of this study (in 2007), they had received
between 4 and 22 ivermectin doses over a 13-year period. We did
not manage to document precisely the history of treatment for the
period 1998–2006 for each participant in the multiply treated
group. Attempts of retrospective interviews showed that this
approach suffers from serious recall bias and official registers used
Figure 5. Observed (grey bars) and predicted (empty bars) distributions of microfilarial density in ivermectin-naı̈ve subjects.
doi:10.1371/journal.pntd.0002084.g005
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by the community distributors during CDTI campaigns were not
available or not fully reliable. Nevertheless, we can assume that a
significant proportion of adult worms present in 2007 in the
multiply treated hosts had been subjected to several rounds of
ivermectin. As indicated by the model (interaction term between
the number of nodules and the study group), the contribution of
adult worms to microfilarial density, for a given number of
nodules, was not different between the groups. Therefore,
observing similar levels of microfilarial density during six months
after administration of a dose of ivermectin in the two groups does
not suggest that, in those female worms which have been
repeatedly targeted by ivermectin, fecundity has been cumulatively
and irreversibly reduced, as it has been proposed in the past [35].
Thus, together with recent findings obtained by Bayesian
modelling of the effect of six-monthly ivermectin treatments on
skin microfilarial density [36], our observations do not support the
operation of a strong cumulative effect of repeated treatments on
the fecundity of female worms. Yet, our present analyses are
strictly based on assessment of mf reappearance in the skin as an
indicator of ivermectin efficacy. Microfilarial density represents
the production of a pool of worms living in the host. Results
presented by Osei-Atweneboana and others [12] suggest that
worms contribute unequally to skin repopulation, possibly those
less sensitive to ivermectin contributing the most to the re-increase
in skin density after multiple treatments. The possibility that the
same pattern occurs in the patients from the Mbam valley cannot
be discarded based on the present results. Further analysis of the
worms’ reproductive status, in particular in those subjects
harbouring the highest microfilarial densities 180 days after
ivermectin, may give a more comprehensive picture of how the
worms have been affected by ivermectin pressure.
One important finding is the demonstration that the microfi-
larial density after treatment is significantly associated with the two
individual level factors included as covariates in the model, namely
age and number of nodules. This holds true both after a first
treatment [27], and after repeated doses of ivermectin (present
data in multiply treated group). Specifically, the number of
nodules seems to have a strong effect on the post-ivermectin
microfilarial density, with any increase in one nodule associated
with a 14.9% increase (conditionally on average values of other
covariates) in microfilarial density during the period of follow-up
(D15–D180). During a previous study conducted in the Mbam
area, we observed that the number of worms per nodule was fairly
constant and independent of the number of palpable nodules [33].
Therefore, we can assume that the number of palpable nodules is
positively correlated with the number of adult worms actually
present in the host. If this assumption is correct, it is not surprising
to observe that the more nodules in the host, the higher the rate of
skin repopulation by mf after ivermectin treatment. This
assumption may not be true in all onchocerciasis foci [37] but,
Figure 6. Observed (grey bars) and predicted (empty bars) distributions of microfilarial density in multiply treated subjects.
doi:10.1371/journal.pntd.0002084.g006
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should it apply in endemic communities of central Ghana, it may
explain, at least partly, the observations of sub-optimal responses
that brought up some controversy regarding the development of
ivermectin resistance [11,38–42]. In the Ghanaian study, a
particularly noteworthy figure is that those communities showing
statistically [28] higher than expected rates of skin repopulation
had higher nodule prevalences (16.1%, 19.3% and 22.9%) than
communities responding as expected (4%, 5.1%, 5.6%, 6.0%,
6.9% and 15.4%). Since nodule prevalence is probably correlated
with the number of adult parasites in the population, the higher
rates of skin repopulation in the four suboptimally responding
Ghanaian communities may be partly due to differences in
intensity of infection, as assessed by nodule prevalence at the time
of the study. Adjusting the individual responses on individual
nodule density may be critical in the assessment and monitoring of
ivermectin efficacy in onchocerciasis. Nonetheless, because the
relationship between the number of nodules and the repopulation
rate may not be linear, inferring this correlation to indicators
relevant at the community level (nodule prevalence and mean
percentage of microfilarial density reduction) certainly requires
further statistical analysis and we would encourage such modelling
studies to be conducted.
One of the most striking observations made during the study
was the high number of nodules harboured by the subjects from
the Mbam valley. As a decrease in the prevalence of nodules
following mass chemotherapy has been documented in several
areas [43,44], such a situation was quite unexpected after 13 years
of repeated ivermectin treatments, including nine years of CDTI
in the whole region. Although it was out of the scope of this study,
we would advocate for assessment of the impact of CDTI in the
area. Persistence of infection after almost a decade of large-scale
treatments may be related to sub-optimal response of the worms to
ivermectin but also to unsatisfactory therapeutic coverage, or both.
We think that the significant association between the number of
palpable nodules and post-ivermectin microfilarial dynamics is an
important finding. It has been argued that the diagnostic value of
nodule palpation tends to be poor in communities with low or
moderate endemicity [45] but the results of the present study show
that the distribution of nodules may have to be considered when
evaluating the impact of ivermectin treatments on the levels of
endemicity of onchocerciasis in those areas that were originally
hyperendemic. Still, we have to keep in mind that for this study,
inclusion criteria required that participants were males presenting
with at least two palpable nodules and the influence of nodules on
the microfilarial density after treatment should be also assessed in
other strata of the population. Further analyses of existing data
including a more representative sample of the general population
(e.g. community trials of ivermectin during which microfilarial
density and palpable nodules would be assessed) should be
encouraged.
Recently, elimination of onchocerciasis using ivermectin alone
has been achieved in some African foci [2,3]. Yet, it is thought to
be feasible only under specific conditions such as both a low to
moderate initial level of endemicity and a high, sustained,
therapeutic coverage. In most parts of Africa, similarly to the
situation in the Mbam valley, annual treatment may not be
effective in efforts to eliminate onchocerciasis. A failed approach
would lead to repeat the treatment virtually indefinitely, and may
well contribute to increased risk of drug resistance. To achieve the
goal of transmission interruption, programme managers should
consider the possibility to provide more frequent rounds of
ivermectin treatments, as well as developing new means to ensure
that maximal therapeutic coverage is reached every year. Beside,
vector control should be considered, in addition to large scale
chemotherapy, in areas where the annual transmission potential is
particularly high [46].
Lastly, some host-related genetic factors may also be responsible
for a fraction of the variability in the response to infection
following ivermectin treatment. Genetic factors driving different
immune response against O. volvulus in the natural course of
infection have been identified [47,48] but their potential role in
ivermectin efficacy against this parasite has still to be assessed.
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